Table 1.
Baseline demographic and clinical characteristics of 41 participants
| Variable | Mean (S.D.) or % |
|---|---|
| Age (years) | 60.2 (6.7) |
| Sex (% male) | 73.2 |
| Race (% white) | 85.4 |
| Diagnosis (%) | |
| Schizophrenia | 80.5 |
| Schizoaffective disorder | 19.5 |
| Illness duration (years) | 34.3 (10.6) |
| Number of inpatient hospitalizations | 5.9 (5.4) |
| Antipsychotic dose (mg/day) | |
| Olanzapine (N=24) | 20.6 (6.7) |
| Risperidone (N=17) | 4.3 (2.4) |
| Combined (Olanzapine equivalentsa; N=41) | 18.0 (7.9) |
| Participants receiving concomitant medications (N) | |
| Antiparkinsonian | 4 |
| Antidepressant | 15 |
| Mood stabilizer | 7 |
| Benzodiazepine | 13 |
| Any of the above | 24 |
| PANSS total score | 60.2 (13.5) |
| BPRS total score | 41.3 (8.7) |
Abbreviations: BPRS: Brief Psychiatric Rating Scale; PANSS: Positive and Negative Syndrome Scale.
a
Calculated using consensus-based antipsychotic dose equivalents based on Gardner et al. (20mg olanzapine = 6 mg risperidone) (Gardner et al. 2010).